Spero Therapeutics (SPRO) Notes Payables (2016 - 2022)

Spero Therapeutics' (SPRO) quarterly Notes Payables came in at $141000.0 in Q3 2022, up 22.61% on a QoQ basis from $115000.0 in Q2 2022.

Spero Therapeutics (SPRO) Notes Payables (2016 - 2022) Analysis & Trends

Spero Therapeutics (SPRO) has 5 years of Notes Payables data on file, last reported at $141000.0 in Q3 2022.

Quarterly Notes Payables changed N/A year-over-year to $141000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $141000.0 (changed N/A YoY) and the FY2018 annual result came in at $223000.0, changed 0.0% from the prior year.
Notes Payables improved to $141000.0 in Q3 2022, from $115000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $995000.0 in Q1 2022 to a low of $115000.0 in Q2 2022.
A 3-year average of $281200.0 and a median of $223000.0 in 2018 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 2.76% in 2018, down 0.0% in 2018.
Tracing SPRO's Notes Payables over 3 years: stood at $223000.0 in 2018, then changed by 0.0% to $223000.0 in 2019, then slumped by 36.77% to $141000.0 in 2022.
The last three Notes Payables figures came in at $141000.0 (Q3 2022), $115000.0 (Q2 2022), and $995000.0 (Q1 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.69 Bn	78.70 Bn	3.93 Bn
3	Argenx Se	65.23 Bn	60.05 Bn	1.37 Bn
4	Moderna	60.16 Bn	55.02 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.86 Bn	28.55 Bn	992.69 Mn
7	BioNTech SE	28.24 Bn	9.85 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	Spero Therapeutics	71.30 Mn	20.52 Mn	-

Download Data